: 89bio’s public stock offering upsized by 38%, priced at a 4% discount


89bio Inc. ETNB, -3.96% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million. The pricing was 4.1% below Thursday’s closing price of $16.94. Late Thursday, the company had said it proposed a public offering of $200 million shares of common stock. The stock tacked on 0.2% in premarket trading. The company took advantage of the stock’s big rally over the past two days, in the wake of the company’s announcement that its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution compared with placebo in a Phase 2b clinical trial. The stock has rocketed 325% over the past 12 months through Thursday, while the iShares Biotechnology exchange-traded fund IBB, +1.22% has lost 4.4% and the S&P 500 SPX, +0.56% fell 12.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articlePersonal Finance Daily: Renters in these cities are spending more than 30% of their income on housing and food insecurity in America reaches the highest level in four years
Next articleThe Moneyist: Do I need to tell prospective buyers that my husband died in the living room of our home? Exactly what must be disclosed before selling a house?


Please enter your comment!
Please enter your name here